{"id":36193,"title":"Groundbreaking Three Drug Treatment for Advanced Breast Cancer Doubles Patient Survival Rates","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2024-10-31T09:01:33+00:00","modified":"2024-10-31T09:01:33+00:00","canonical_url":"https://stockmark.it/groundbreaking-three-drug-treatment-for-advanced-breast-cancer-doubles-patient-survival-rates/","markdown_url":"https://stockmark.it/groundbreaking-three-drug-treatment-for-advanced-breast-cancer-doubles-patient-survival-rates.md","json_url":"https://stockmark.it/groundbreaking-three-drug-treatment-for-advanced-breast-cancer-doubles-patient-survival-rates.json","category":"Healthcare","categories":["Healthcare","Medical Research","Pharmaceutical"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/stencil.default-2024-10-31T090119.574.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"A revolutionary combination of three drugs has demonstrated remarkable success in doubling survival times for patients battling incurable breast cancer, according to a landmark clinical trial. The research, spearheaded by the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust, signals a potential transformation in treatment protocols for the 61,000 UK women currently managing advanced breast cancer.\n\nThe comprehensive study, encompassing 325 patients across 28 countries, revealed striking outcomes. Participants receiving the innovative three-drug combination, comprising inavolisib, palbociclib, and fulvestrant, exhibited an average progression-free survival period of 15 months – twice that of the control group. The data showed 46% of treated patients demonstrated no disease progression after 18 months, compared to merely 21% in the placebo group.\n\nThe financial implications for healthcare providers are significant. While palbociclib and fulvestrant are currently available through the NHS, inavolisib – recently approved in the United States – targets a specific protein produced by the PIK3CA gene mutation, present in approximately one-third of breast cancer cases. This mutation, found in 35-40% of hormone receptor positive cases, has been linked to accelerated tumour growth and treatment resistance.\n\nThe market impact could be substantial, particularly for pharmaceutical company Roche, which funded the international study. The treatment’s effectiveness in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer – representing 70% of cases – suggests significant commercial potential.\n\nProfessor Nicholas Turner, the study’s lead author, emphasised the breakthrough’s significance, noting its potential to prevent cancer developing resistance to therapy. With breast cancer affecting 55,000 women annually in the UK and claiming 11,500 lives, the economic and social benefits of this advancement could be far-reaching.\n\nThe findings, published in the New England Journal of Medicine, represent a crucial step forward in oncology treatment. Healthcare economists anticipate this development could substantially influence both treatment protocols and healthcare budgeting decisions in the coming years."}